UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000030392
Receipt No. R000034259
Scientific Title Development of treatment strategy for CKD-MBD by multilateral mechanism of ethelcarcitrate hydrochloride
Date of disclosure of the study information 2018/01/01
Last modified on 2018/05/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Development of treatment strategy for CKD-MBD by multilateral mechanism of ethelcarcitrate hydrochloride
Acronym The DUET study
Scientific Title Development of treatment strategy for CKD-MBD by multilateral mechanism of ethelcarcitrate hydrochloride
Scientific Title:Acronym The DUET study
Region
Japan

Condition
Condition Secondary hyperparathyroidism
Classification by specialty
Medicine in general Endocrinology and Metabolism Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the efficacy of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Ratio of achievement of more than 50% reduction and under 240pg/dl in intact parathyroid hormone (iPTH) after 12 weeks of treatment
Key secondary outcomes -Ratio of achievement of 60<=iPTH<=240 after 12 weeks of treatment
-Ratio of achievement of more than 30% reduction in iPTH after 12 weeks of treatment
-Ratio of achievement of more than 30% reduction and 60<=iPTH<=240 after 12 weeks of treatment
-Ratio of achievement of more than 50% reduction in iPTH after 12 weeks of treatment
-Change in iPTH after 2, 4, 6, 8, 10 and 12 weeks of treatment relative to the baseline
-Change in CalciProtein Particle (CPP) and Fibroblast Growth Factor 23 (FGF23) after 6 and 12 weeks of treatment relative to the baseline among treatment groups
-Change in Ca, P, CaXP and Mg after2, 4, 6, 8, 10 and 12 weeks relative to the baseline among treatment groups
-Change in Bone Specific Alkaline Phosphatase (BAP) and Tartrate-resistant Acid Phosphatase 5b (TRACP5b) after one year of treatment relative to the baseline among treatment groups
-Comparison of aortic calcification before and after observation
-Ca, P and iPTH levels after one year of treatment
-Comparison of normalized ratio of hypocalcemia between VitD and calcium preparations
-Adverse events

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification YES
Dynamic allocation YES
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking YES
Concealment Central registration

Intervention
No. of arms 3
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Etelcalcetide+active Vitamin D for 12weeks
Interventions/Control_2 Etelcalcetide+oral calcium (calcium carbonate) for 12weeks
Interventions/Control_3 Control [active Vitamin D + oral calcium (calcium carbonate)] for 12weeks
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
100 years-old >
Gender Male and Female
Key inclusion criteria 1.patients on maintenance hemodialysis 3 times a week
2.patients with more than one-year hemodialysis vintage
3.patients who are judged stable
4.older than 20 years and younger than 100 years
5.iPTH >=240 pg/ml within 4 months
6.corrected Ca >=8.4mg/dl at enrollment
7.patients who are able to write informed consent
Key exclusion criteria 1.patients who have been prescribed etelcalcetide before
2.bisphosphonate users within 24 weeks
3.primary hyperparathyroidism
4.undergoing parathyroidectomy or intervention therapy to parathyroid within 90 days before enrollment
5.scheduled parathyroidectomy, intervention therapy to parathyroid or kidney plantation
6. pregnant or breast feeding
7. patients who are deemed unsuitable by a physician, for instance cancer, severe infection and severe complication
8. patients who are prescribed Maxacalcitol, over 10[micro]gx3/week at obtainment of IC
9. patients who are prescribed Calcitriol, over 0.75[micro]gx3/week at obtainment of IC
10. patients who are prescribed other active VitD, over half of maximum dose at obtainment of IC
11. patients who are prescribed precipitated calcium carbonate, over 3g/day at obtainment of IC
Target sample size 120

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Shoichi Maruyama
Organization Nagoya University Graduate School of Medicine, Internal Medicine
Division name Nephrology
Zip code
Address 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
TEL +81-52-744-2192
Email marus@med.nagoya-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Sawako Kato
Organization Nagoya University Graduate School of Medicine, Internal Medicine
Division name Nephrology
Zip code
Address 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
TEL +81-52-744-2192
Homepage URL
Email Kato07@med.nagoya-u.ac.jp

Sponsor
Institute Nagoya University Graduate School of Medicine, Nephrology
Institute
Department

Funding Source
Organization ONO PHARMACEUTICAL CO., LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 01 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2018 Year 01 Month 01 Day
Date of IRB
Anticipated trial start date
2018 Year 01 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 12 Month 14 Day
Last modified on
2018 Year 05 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034259

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.